Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease

AIM: To investigate the therapeutic potential of tesevatinib (TSV), a unique multi-kinase inhibitor currently in Phase II clinical trials for autosomal dominant polycystic kidney disease (ADPKD), in well-defined rodent models of autosomal recessive polycystic kidney disease (ARPKD). METHODS: We admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweeney, William E, Frost, Philip, Avner, Ellis D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500456/
https://www.ncbi.nlm.nih.gov/pubmed/28729967
http://dx.doi.org/10.5527/wjn.v6.i4.188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500456/
https://www.ncbi.nlm.nih.gov/pubmed/28729967
http://dx.doi.org/10.5527/wjn.v6.i4.188

Ejemplares similares